18800-37-8

Basic information

• Product Name: 1-(2-BROMOETHOXY)-2-NITROBENZENE
• Synonyms: 1-(2-BROMOETHOXY)-2-NITROBENZENE;2-(2-Nitrophenoxy)ethyl bromide;2-Nitrophenoxyethylbromide;1-(4-Bromoethoxy)-2-nitrobenzene;1-(2-Bromoethoxy)-2-nitrobenzene 98%;1-(2-Bromoethoxy)-2-nitrobenzene,99%;1-(2-Bromoethoxy)-2-nitrobenzene98%
• CAS NO: 18800-37-8
• Molecular Formula: C₈H₈BrNO₃
• Molecular Weight: 246.06
• Product Categories: blocks;Bromides;NitroCompounds
• Mol File: 18800-37-8.mol

Chemical Properties

• Melting Point: 40-44 °C
• Boiling Point: 127-130 °C (0.5 mmHg)
• Flash Point: 160.3 °C
• Appearance: /
• Density: 1.587g/cm³
• Vapor Pressure: 0.000158mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1-(2-BROMOETHOXY)-2-NITROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMOETHOXY)-2-NITROBENZENE(18800-37-8)
• EPA Substance Registry System: 1-(2-BROMOETHOXY)-2-NITROBENZENE(18800-37-8)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-22
• Safety Statements: 37/39-26
• Hazardous Substances Data: 18800-37-8(Hazardous Substances Data)

Usage

Chemical Properties

yellow crystalline powder

InChI:InChI=1/C8H8BrNO3/c9-5-6-13-8-4-2-1-3-7(8)10(11)12/h1-4H,5-6H2

Upstream product

• 824-39-5 sodium o-nitrophenate 
• 106-93-4 ethylene dibromide 
• 88-75-5 2-hydroxynitrobenzene 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 5409-77-8 (2-bromo-ethyl)-(4-chloromethyl-2-nitro-phenyl)-ether 
• 99542-02-6 2-[2-(2-nitro-phenoxy)-ethoxy]-benzoic acid 
• 125174-42-7 Methyl-[2-(2-nitro-phenoxy)-ethyl]-[2-(4-nitro-phenyl)-ethyl]-amine 
• 19223-12-2 N-{3-[2-(2-Nitro-phenoxy)-ethoxy]-phenyl}-acetamide 
• 190449-07-1 4-[2-(2-nitro-phenoxy)-ethoxy]-benzoic acid ethyl ester 
• 308101-20-4 1,5-bis(2-nitrophenoxy)-3-azapentane 
• 96315-08-1 1-(5'-methyl-2'-nitrophenoxy)-2-(2''-nitrophenoxy)ethane 
• 312739-05-2 C₆₂H₇₄N₂O₁₀ 
• 374588-03-1 2-(1-oxa-4-azahept-6-enyl)nitrobenzene 
• 96331-95-2 1-(2'-amino-5'-methylphenoxy)-2-(2''-aminophenoxy)ethane 
• 246857-46-5 2-[(N-methylsulfonyl)-4-aza-7-formyl-1-oxaheptyl]nitrobenzene 
• 374588-04-2 2-[(N-methylsulfonyl)-1-oxa-4-azahept-6-enyl]nitrobenzene 

Relevant articles and documents

Macrometallocycle binuclear NHC silver(I) complex with bridging azobenzene: Synthesis, structure and recognition for hydrogen sulfate

One bis-imidazolium salt 2,2′-di[2’’-(N-methyl-imidazoliumyl)ethoxyl]azobenzene hexafluorophosphate (LH2·(PF6)2) and its macrometallocycle binuclear N-heterocyclic carbene silver(I) complex [(LAg)2](PF6/su

Microsphere-based real-time calcium sensing

Sensing within the cell: Microspheres (2 μm) covalently loaded with calcium sensors can be delivered efficiently into living cells to analyze the intracellular changes in the concentration of Ca2+ ions in real time. The figure shows the real-ti

Synthesis of an azido-tagged low affinity ratiometric calcium sensor

Changes in high localised concentrations of Ca2+ ions are fundamental to cell signalling. The synthesis of a dual excitation, ratiometric calcium ion sensor with a Kd of 90 μM, is described. It is tagged with an azido group for bioconjugation, and absorbs in the blue/green and emits in the red region of the visible spectrum with a large Stokes shift. The binding modulating nitro group is introduced to the BAPTA core prior to construction of a benzofuran-2-yl carboxaldehyde by an allylation-oxidation-cyclisation sequence, which is followed by condensation with an azido-tagged thiohydantoin. The thiohydantoin unit has to be protected with an acetoxymethyl (AM) caging group to allow CuAAC click reaction and incorporation of the KDEL peptide endoplasmic reticulum (ER) retention sequence.

CONJUGATES AND CONJUGATES FOR USE IN PREVENTING OR TREATING OF BRAIN DAMAGE AND NEURODEGENERATIVE DISEASES

The present invention relates to conjugates comprising one or more compounds selected from of (i) an anti-inflammatory compound, and/or (ii) an antioxidant compound, and/or (iii) and antibiotic compound and/or, (iv) a metal chelating compound and at least

A Comprehensive Study of the Ca2+ Ion Binding of Fluorescently Labelled BAPTA Analogues

Since its development, the ionophore BAPTA (1,2-bis(2-aminophenoxy)-ethane-N,N,N’,N’-tetraacetic acid) has been used unchanged in calcium sensing applications. In this work we present a comprehensive experimental and theoretical study of novel alterations in the structure of BAPTA, with a focus on the systematic modification of the chain connecting the two aromatic rings of the molecule (denoted as “linker”). A bis-(diethylamino)xantene fluorophore was also attached to the structures in a fixed position and the structure-fluorescence response relationship of these molecules was investigated in addition. The effect of the linker's length, the number of oxygen atoms in this chain and even the removal of one of the rings was tested; these all proved to significantly alter the characteristics of the compounds. For example, it was found that the second aromatic ring of BAPTA is not essential for the turn-on of the fluorescence. We also demonstrated that successful sensing can be realized even by replacing the chain with a single oxygen atom, which suggests the availability of a new calcium binding mode of the chelator. The reliable turn-on characteristic, the steep Ca2+ fluorescence titration curve and the intense fluorescence emission combine to make this compound a prospective candidate as a calcium sensing molecular probe in diagnostic neurobiological applications.

Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach

The overexpression of PTP-LAR could cause the insulin resistance, so PTP-LAR might be a promising target for treating diabetes. In this study, we applied the computer modeling methods with fragment replace approach to screen the fragment database by targeting PTP domain and site B with the aim to discover potent and selective PTP-LAR inhibitors. A series of novel 4-thiazolidone derivatives were gained. The results of their ADMET predictions indicated that these new compounds might become drug candidates. The series of these derivatives were synthesized. Subsequently, their PTP-LAR inhibitory activities were assayed. The compound7d showed highly selectivity for PTP-LAR (10.41 μM) over its close homolog PTP1B (IC50=44.40 μM), SHP2 (IC50>122.81 μM) and CDC25B (IC50>122.81 μM) and docking and molecular dynamics simulation were applied to propose the most likely binding mode of compound7d with PTP-LAR. Thus, our findings reported here may pave a way for discovering potential selective PTP-LAR inhibitors. AbbreviationsPTP-LAR Human leukocyte common antigen-relatedPTP Protein Tyrosine PhosphataseIR insulin receptorPTP1B Protein tyrosine phosphatase-1BLRP Lung resistance proteinADMET absorption, distribution, metabolism, excretion, toxicityPPB plasma protein bindingBBB blood brain barrier penetrationCYP450 cytochrome P450HIA human intestinal absorptionTLC thin-layer chromatographyUV Ultra VioletNMR nuclear magnetic resonanceTMS tetramethylsilaneMS mass spectrometryANM anisotropic network modePDB Protein Data BankDMF N,N-DimethylformamidepNPP para-nitrophenyl phosphateDTT dithiothreitolMD molecular dynamicRMSD root-mean-square deviationRMSF root-mean-square fluctuationSPC single-point chargePME Particle Mesh EwaldMM-PBSA molecular mechanics Poisson Boltzmann surface areaH bond, hydrogen bondVDW Van der Waals Communicated by Ramaswamy H. Sarma.

METHODS FOR PREPARING FUEL ADDITIVES

A method is provided for preparing a fuel additive having the formula: ( l ) The method comprises carrying out the following reactions: (i) addition of an alkylating agent b to starting material a: (a) to form an intermediate c; and (ii) ring closing intermediate c to form fuel additive e.

Synthesis of new chalcone-based homoserine lactones and their antiproliferative activity evaluation

Three series of new homoserine lactone analogs were efficiently synthesized starting from methionine and further evaluated for their antiproliferative activity against different cancer cell lines. Among these compounds, some of the chalcone containing compounds 6a-n showed acceptable antiproliferative activity against prostate cancer cells DU145 and PC-3 with the IC50 values less than 10 μM. Compounds 6c, 6e and 6h inhibited growth of DU145 and PC-3 cells at low micromolar levels with the IC50 values ranging from 3.0 to 5.0 μM, much more potent than natural OdDHL. Compound 6e concentration-dependently inhibited colony formation and cell migration of DU145 cells. A synergistic effect on the growth inhibition and the apoptosis of DU145 cells was observed when compound 6e was used in combination with TRAIL. OdDHL or 6e treatment concentration-dependently activated TRAIL death receptor DR5 which may account for the observed synergistic effect of 6e or OdDHL with TRAIL on the growth inhibition and cell apoptosis. Compound 6e also inhibited migration of DU145 cells in a time- and concentration-dependent manner. The data suggest that quorum sensing molecules OdDHL and 6e may improve the sensitivity of DU145 cells toward TRAIL via activating DR5, compound 6e may be used as a potential lead compound for developing new TRAIL receptor agonists.

Azobenzene linked cyclic N-heterocyclic carbene silver complex as well as preparation method and application thereof

The invention discloses an azobenzene linked cyclic N-heterocyclic carbene silver complex as well as a preparation method and application thereof. The preparation method comprises the following steps:reacting o-nitrophenol and 1,2-dibromoethane in an orga

Targeted probes of cellular physiology

Biosensor comprising an activatable acceptor fluorogen linked via a linker to a donor which transfers energy to the fluorogen on detecting an analyte wherein the fluorogen component reacts and a 100 fold increase in intensity results when the fluorogen interacts non-covalently with an activator e.g. fluorogen activator peptide.